Ralinepag Reduces Pulmonary Vascular Resistance (PVR) in a Phase 2 Study Confirming Preclinical Findings on Prostacyclin (IP) Receptors in Human Tissues

Preston, IR; Shen, L; Patel, J; Sood, N; Torres, F; Cadaret, L; Adams, J; Preston, IR; Shen, L; Patel, J; Sood, N; Torres, F; Cadaret, L; Adams, J; Clapp, L; - view fewer (2018) Ralinepag Reduces Pulmonary Vascular Resistance (PVR) in a Phase 2 Study Confirming Preclinical Findings on Prostacyclin (IP) Receptors in Human Tissues. Presented at: Chest Annual Meeting 2018, San Antonio (TX), USA.

https://ift.tt/2PLO3Nv